CLINICAL TRIALS PROFILE FOR CLOPIDOGREL BISULFATE
✉ Email this page to a colleague
All Clinical Trials for clopidogrel bisulfate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00020189 ↗ | Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2000-06-01 | RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or metastatic head and neck cancer. |
| NCT00263211 ↗ | A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients | Terminated | Barnes-Jewish Hospital | Phase 2 | 2006-01-01 | The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer. |
| NCT00263211 ↗ | A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients | Terminated | Washington University School of Medicine | Phase 2 | 2006-01-01 | The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer. |
| NCT00528411 ↗ | A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin | Completed | AstraZeneca | Phase 2 | 2007-10-01 | The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated how long it takes for Ticagrelor to begin working and how long it takes for it to stop working after the last dose of drug. Ticagrelor will be compared to clopidogrel, an established anti-platelet treatment for preventing blood clots, and placebo plus Aspirin. |
| NCT00648947 ↗ | Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2004-12-01 | The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered under fasting conditions. |
| NCT00650169 ↗ | Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2004-12-01 | The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered under fed conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for clopidogrel bisulfate
Condition Name
Clinical Trial Locations for clopidogrel bisulfate
Trials by Country
Clinical Trial Progress for clopidogrel bisulfate
Clinical Trial Phase
Clinical Trial Sponsors for clopidogrel bisulfate
Sponsor Name
